Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
Autor: | Michael Reiss, Daniel Zelterman, Rebecca Sipples, Vinni Juneja, Frans J. Th. Wackers, Bruce G. Haffty, Forrester A. Lee, Maysa M. Abu-Khalaf, Michael P. DiGiovanna, Meghan McGurk, Gina G. Chung, Barbara Burtness |
---|---|
Rok vydání: | 2006 |
Předmět: |
Cancer Research
medicine.medical_specialty Cyclophosphamide Anthracycline Heart Diseases Paclitaxel medicine.medical_treatment Urology Breast Neoplasms Drug Administration Schedule Breast cancer Antineoplastic Combined Chemotherapy Protocols medicine Adjuvant therapy Humans Aged Chemotherapy Cardiotoxicity Ejection fraction business.industry Heart Middle Aged medicine.disease Surgery Regimen Treatment Outcome Oncology Chemotherapy Adjuvant Doxorubicin Female business medicine.drug Follow-Up Studies |
Zdroj: | Breast cancer research and treatment. 104(3) |
ISSN: | 0167-6806 |
Popis: | This study evaluated the incidence of late cardiotoxicity after dose-dense and -intense adjuvant sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) for breast cancer (BC) with ≥ 4 involved ipsilateral axillary lymph nodes. Patients were enrolled from 1994 to 2001 after definitive BC surgery if ≥4 axillary nodes were involved. Planned treatment was A 90 mg/m2 q 14 days × 3, T 250 mg/m2 q 14 days × 3, C 3 g/m2 q 14 days × 3 with filgrastim (G) support. Left ventricular ejection fraction (LVEF) was monitored using equilibrium radionuclide angiography (ERNA) before the initiation of chemotherapy, and after three cycles of each chemotherapeutic agent. At a median follow-up of 7 years, we obtained ERNA scans on 32 patients to evaluate the long-term cardiotoxicity of this regimen. Eighty-five eligible patients enrolled on the treatment protocol. Clinical heart failure developed in one patient. Seven (8%) patients had LVEF |
Databáze: | OpenAIRE |
Externí odkaz: |